G protein-regulated signaling dysfunction in human disease

Journal of Investigative Medicine

Volumn 51, Issue 4, 2003, Pages 194-214

  Simonds, William F ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN RECEPTOR KINASE; UNCLASSIFIED DRUG;

ACROMEGALY; AUTOSOMAL DOMINANT DISORDER; BINDING SITE; BIOINFORMATICS; CARNEY COMPLEX; CLINICAL FEATURE; CONGENITAL STATIONARY NIGHT BLINDNESS; GENE MUTATION; GENOME; GUANINE NUCLEOTIDE BINDING PROTEIN SIGNALING DYSFUNCTION; HUMAN; LIGAND BINDING; LINKAGE ANALYSIS; MOLECULAR BIOLOGY; NIGHT BLINDNESS; NONAUTOIMMUNE AUTOSOMAL DOMINANT HYPERTHYROIDISM; PATHOPHYSIOLOGY; PHOTOTRANSDUCTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETINITIS PIGMENTOSA; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AUTOSOMAL DOMINANT INHERITANCE; DISEASES; DOWN REGULATION; HYPERTHYROIDISM; MOLECULAR PATHOLOGY; PROTEIN FUNCTION; PROTEIN STRUCTURE;

EID: 0038504710     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-51-04-21     Document Type: Review

References (215)

1. Sutherland EW, Rall TW. The relation of adenosine-3′,5′-phosphate and phosphorylase to the actions of catecholamines and other hormones. Pharmacol Rev 1960;12:265-99.
2. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 1998;80:231-64.
3. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-50.
4. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999;18:1723-9.
5. Hall RA, Lefkowitz RJ. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res 2002;91:672-80.
6. Brzostowski JA, Kimmel AR. Signaling at zero G: G-protein-independent functions for 7-TM receptors, Trends Biochem Sci 2001;26:291-27.
7. Heuss C, Gerber U. G-protein-independent signaling by G-protein-coupled receptors. Trends Neurosci 2000;23:469-75.
8. 2. Cell 1995;83:1047-58.
9. Lambright DG, Sondek J, Bohm A, et al. The 2.0 Å crystal structure of a heterotrimeric G protein. Nature 1996;379:311-9.
10. sa.GTPgS. Science 1997;278:1907-16.
11. Slep KC, Kercher MA, He W, et al. Structural determinants for regulation of phosphodiesterase by a G protein at 2.0 Å. Nature 2001;409:1071-7.
12. Hamm HE, Gilchrist A. Heterotrimeric G proteins. Curr Opin Cell Biol 1996;8:189-96.
13. Hepler JR. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999;20:376-82.
14. De Vries L, Zheng B, Fischer T, et al. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 2000;40:235-71.
15. Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000;69:795-827.
16. 13. Science 1998;280:2109-11.
17. Fukuhara S, Murga C, Zohar M, et al. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J Biol Chem 1999;274:5868-79.
18. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001;22:368-76.
19. Cabrera JL, De Freitas F, Satpaev DK, Slepak VZ. Identification of the Gb5-RGS7 protein complex in the retina. Biochem Biophys Res Commun 1998;249:898-902.
20. b5 subunits. Proc Natl Acad Sci U S A 1998;95:13307-12.
21. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999;340:1012-20.
22. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-48.
23. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
24. Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2001;2:116-22.
25. Arvanitakis L, Geras-Raaka E, Varma A, et al. Human herpes-virus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997;385:347-50.
26. Yang TY, Chen SC, Leach MW, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000;191:445-54.
27. Lerman BB, Dong B, Stein KM, et al. Right ventricular outflow tract tachycardia due to a somatic cell mutation in G protein subunitalphai2. J Clin Invest 1998;101:2862-8.
28. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297-303.
29. Brown EM. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Metab Clin North Am 2000;29:503-22.
30. Patten JL, Johns DR, Valle D, et al. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med 1990;322:1412-9.
31. Weinstein LS, Yu S. The role of genomic imprinting of G-alpha in the pathogenesis of Albright hereditary osteodystrophy. Trends Endocrinol Metab 1999;10:81-5.
32. Weinstein LS, Yu SH, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein a-subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675-705.
33. Shenker A, Chanson P, Weinstein LS, et al. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet 1995;4:1675-6.
34. Alman BA, Greel DA, Wolfe HJ. Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res 1996;14:311-35.
35. Bianco P, Riminucci M, Majolagbe A, et al. Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 2000;15:120-8.
36. Liu G, Duranteau L, Carel JC, et al. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 1999;341:1731-6.
37. Shenker A, Laue L, Kosugi S, et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993;365:652-64.
38. Berson EL. Retinitis pigmentosa and allied diseases. In: Albert DM, Jakobiec FA, Azar DT, Gragoudas ES, editors. Principles and practice of ophthalmology. Philadelphia: WB Saunders;2000. p. 2262-90.
39. Dryja TP, McGee TL, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990;343:364-6.
40. Olsson JE, Gordon JW, Pawlyk BS, et al. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 1992;9:815-30.
41. Naash MI, Hollyfield JG, al-Ubaidi MR, Baehr W. Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene. Proc Natl Acad Sci U S A 1993;90:5499-503.
42. Illing ME, Rajan RS, Bence NF, Kopito RR. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J Biol Chem 2002;277:34150-60.
43. Saliba RS, Munro PM, Luthert PJ, Cheetham ME. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J Cell Sci 2002;115:2907-18.
44. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002;58:179-85.
45. Keen TJ, Inglehearn CF, Lester DH, et al. Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. Genomics 1991;11:199-205.
46. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD. Constitutively active mutants of rhodopsin. Neuron 1992;9:719-25.
47. Li T, Franson WK, Gordon JW, et al. Constitutive activation of phototransduction by K296E opsin is not a cause of photoreceptor degeneration. Proc Natl Acad Sci U S A 1995;92:3551-5.
48. Sung CH, Makino C, Baylor D, Nathans J. A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J Neurosci 1994;14:5818-33.
49. Li T, Snyder WK, Olsson JE, Dryja TP. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc Natl Acad Sci U S A 1996;93:14176-81.
50. Portera-Cailliau C, Sung CH, Nathans J, Adler R. Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A 1994;91:974-98.
51. Berson EL, Rosner B, Weigel-DiFranco C, et al. Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci 2002;43:3027-36.
52. Rosenfeld PJ, Cowley GS, McGee TL, et al. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat Genet 1992;1:209-13.
53. Huang SH, Pittler SJ, Huang X, et al. Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. Nat Genet 1995;11:468-71.
54. McLaughlin ME, Sandberg MA, Berson EL, Dryja TP. Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nat Genet 1993;4:130-4.
55. Weitz CJ, Went LN, Nathans J. Human tritanopia associated with a third amino acid substitution in the blue-sensitive visual pigment. Am J Hum Genet 1992;51:444-6.
56. Bareil C, Hamel CP, Delague V, et al. Segregation of a mutation in CNGB1 encoding the beta-subunit of the rod cGMP-gated channel in a family with autosomal recessive retinitis pigmentosa. Hum Genet 2001;108:328-34.
57. McKusick VA. Mendelian Inheritance in Man. A catalog of human genes and genetic disorders. Baltimore: Johns Hopkins University Press; 1998.
58. Dryja TP, Berson EL, Rao VR, Oprian DD. Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet 1993;4:280-3.
59. Sieving PA, Richards JE, Naarendorp F, et al. Dark-light: model for night blindness from the human rhodopsin Gly-90→Asp mutation. Proc Natl Acad Sci U S A 1995;92:880-4.
60. Rao VR, Cohen GB, Oprian DD. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 1994;367:639-42.
61. Sieving PA, Fowler ML, Bush RA, et al. Constitutive "light" adaptation in rods from G90D rhodopsin: a mechanism for human congenital nightblindness without rod cell loss. J Neurosci 2001;21:5449-60.
62. Dryja TP, Hahn LB, Reboul T, Arnaud B. Missense mutation in the gene encoding the alpha subunit of rod transducin in the Nougaret form of congenital stationary night blindness. Nat Genet 1996;13:358-60.
63. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991;349:117-27.
64. Krengel U, Schlichting L, Scherer A, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 1990;62:539-48.
65. Sandberg MA, Pawlyk BS, Dan J, et al. Rod and cone function in the Nougaret form of stationary night blindness. Arch Ophthalmol 1998;116:867-72.
66. Muradov KG, Artemyev NO. Loss of the effector function in a transducin-alpha mutant associated with Nougaret night blindness. J Biol Chem 2000;275:6969-74.
67. Gal A, Orth U, Baehr W, et al. Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness. Nat Genet 1994;7:64-8.
68. Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993;365:649-51.
69. Duprez L, Parma J, Van Sande J, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994;7:396-401.
70. 2-adrenergic receptor. J Biol Chem 1993;268:16483-7.
71. Fuhrer D, Wonerow P, Willgerodt H, Paschke R. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism. J Clin Endocrinol Metab 1997;82:4234-8.
72. Kopp P, Jameson JL, Roe TF. Congenital nonautoimmune hyperthyroidism in a nonidentical twin caused by a sporadic germline mutation in the thyrotropin receptor gene. Thyroid 1997;7:765-70.
73. Khoo DH, Parma J, Rajasoorya C, et al. A germline mutation of the thyrotropin receptor gene associated with thyrotoxicosis and mitral valve prolapse in a Chinese family. J Clin Endocrinol Metab 1999;84:1459-62.
74. Tonacchera M, Van Sande J, Cetani F, et al. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 1996;81:547-54.
75. Biebermann H, Schoneberg T, Hess C, et al. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J Clin Endocrinol Metab 2001;86:4429-33.
76. Lee YS, Poh L, Loke KY. An activating mutation of the thyrotropin receptor gene in hereditary non-autoimmune hyperthyroidism. J Pediatr Endocrinol Metab 2002;15:211-25.
77. Alberti L, Proverbio MC, Costagliola S, et al. A novel germline mutation in the TSH receptor gene causes nonautoimmune autosomal dominant hyperthyroidism. Eur J Endocrinol 2001;145:249-54.
78. Schwab KO, Gerlich M, Broecker M, et al. Constitutively active germline mutation of the thyrotropin receptor gene as a cause of congenital hyperthyroidism. J Pediatr 1997;131:899-904.
79. Gruters A, Schoneberg T, Biebermann H, et al. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J Clin Endocrinol Metab 1998;83:1431-6.
80. Tonacchera M, Agretti P, Rosellini V, et al. Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene. Thyroid 2000;10:859-63.
81. Esapa CT, Duprez L, Ludgate M, et al. A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis. Thyroid 1999;9:1005-10.
82. Melmed S, Ho K, Klibanski A, et al. Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-402.
83. Barkan AL. New options for diagnosing and treating acromegaly. Cleve Clin J Med 1998;65:343, 347-9.
84. Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab 1999;84:4379-484.
85. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:566-8.
86. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-6.
87. Yang I, Park S, Ryu M, et al. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 1996;134:720-76.
88. Yoshimoto K, Iwahana H, Fukuda A, et al. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 1993;72:1386-193.
89. Shi Y, Tang D, Deng J, Su C. Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors. Chin Med J (Engl) 1998;111:891-4.
90. Kim HJ, Kim MS, Park YJ, et al. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas. J Endocrinol 2001;168:221-6.
91. Hosoi E, Yokogoshi Y, Hosoi E, et al. Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinol (Copenh) 1993;129:301-36.
92. s protein. J Clin Endocrinol Metab 1990;71:1416-20.
93. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655-69.
94. Johnson MC, Codner E, Eggers M, et al. Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors. J Pediatr Endocrinol Metab 1999;12:381-7.
95. Sa. Science 1997;278:1943-7.
96. ia1 and the mechanism of GTP hydrolysis. Science 1994;265:1405-12.
97. Sondek J, Lambright DG, Noel JP, et al. GTPase mechanism of G proteins from the 1.7-A crystal structure of transducin alpha-GDP-AIF-4. Nature 1994;372:276-9.
98. Bourne HR, Landis CA, Masters SB. Hydrolysis of GTP by the alpha-chain of Gs and other GTP binding proteins. Proteins 1989;6:222-30.
99. Freissmuth M, Gilman AG. Mutations of GS alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity. J Biol Chem 1989;264:21907-14.
100. Carney JA, Hruska LS, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 1986;61:165-72.
101. Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985;64:270-83.
102. Stratakis CA. Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes. J Endocrinol Invest 2001;24:370-83.
103. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041-6.
104. Carney JA. Differences between nonfamilial and familial cardiac myxoma. Am J Surg Pathol 1985;9:53-5.
105. Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996;97:699-705.
106. Casey M, Mah C, Merliss AD, et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 1998;98:2560-6.
107. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
108. Kirschner LS, Sandrini F, Monbo J, et al. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000;9:3037-46.
109. Casey M, Vaughan CJ, He J, et al. Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest 2000;106:R31-8.
110. Michel JJ, Scott JD. Akap mediated signal transduction. Annu Rev Pharmacol Toxicol 2002;42:235-57.
111. Tasken K, Skalhegg BS, Tasken KA, et al. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997;31:191-204.
112. Burton KA, Johnson BD, Hausken ZE, et al. Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1997;94:11067-72.
113. Amieux PS, Cummings DE, Motamed K, et al. Compensatory regulation of RIalpha protein levels in protein kinase A mutant mice. J Biol Chem 1997;272:3993-8.
114. Felder RA, Sanada H, Xu J, et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A 2002;99:3872-7.
115. Fuchs S, Nakazawa M, Maw M, et al. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet 1995;10:360-2.
116. Yamamoto S, Sippel KC, Berson EL, Dryja TP. Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. Nat Genet 1997;15:175-8.
117. Cheong HI, Park HW, Ha IS, et al. Six novel mutations in the vasopressin V2 receptor gene causing nephrogenic diabetes insipidus. Nephron 1997;75:431-47.
118. Gherman RB, Bowen E, Eggleston MK, et al. Successful pregnancy outcome in a woman with a gain-of-function mutation of the calcium-sensing receptor. A case report. J Reprod Med 1999;44:745-77.
119. Baldwin JM, Schertler GF, Unger VM. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997;272:144-64.
120. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-45.
121. Muller G. Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr Med Chem 2000;7:861-88.
122. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 1989;86:7321-5.
123. Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001;299:268-76.
124. Chen G, Way J, Armour S, et al. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 2000;57:125-34.
125. Pausch MH. G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery. Trends Biotechnol 1997;15:487-94.
126. Broach JR, Thorner J. High-throughput screening for drug discovery. Nature 1996;384:14-6.
127. Klein I. Validation of genomics-derived drug targets using yeast. Drug Discov Today 2000;5:37-8.
128. Ijzerman A, Kourounakis A, van der Klein P. Allosteric modulation of G protein-coupled receptors. Farmaco 2001;56:67-70.
129. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 1999;10:66-71.
130. Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1083-8.
131. Knoflach F, Mutel V, Jolidon S, et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A 2001;98:13402-7.
132. Musser B, Mudumbi RV, Liu J, et al. Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. J Pharmacol Exp Ther 1999;288:446-54.
133. Birdsall NJ, Lazareno S, Popham A, Saldanha J. Multiple allosteric sites on muscarinic receptors. Life Sci 2001;68:2517-24.
134. Fawzi AB, Macdonald D, Benbow LL, et al. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol Pharmacol 2001;59:30-7.
135. Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002;42:409-35.
136. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-9.
137. Aldecoa A, Gujer R, Fischer JA, Born W. Mammalian calcitonin receptor-like receptor/receptor activity modifying protein complexes define calcitonin gene-related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells. FEBS Lett 2000;471:156-60.
138. Hilairet S, Foord SM, Marshall FH, Bouvier M. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 2001;276:29575-81.
139. Brakeman PR, Lanahan AA, O'Brien R, et al. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 1997;386:284-8.
140. Beneken J, Tu IC, Xiao B, et al. Structure of the Homer EVH1 domain-peptide complex reveals a new twist in polyproline recognition. Neuron 2000;26:143-54.
141. Tadokoro S, Tachibana T, Imanaka T, et al. Involvement of unique leucine-zipper motif of PSD-Zip45 (Homer 1c/vesl-1L) in group 1 metabotropic glutamate receptor clustering. Proc Natl Acad Sci U S A 1999;96:13801-6.
142. Ciruela F, Soloviev MM, Chan WY, McIlhinney RA. Homer-1c/Vesl-1L modulates the cell surface targeting of metabotropic glutamate receptor type 1alpha: evidence for an anchoring function. Mol Cell Neurosci 2000;15:36-50.
143. Becamel C, Alonso G, Galeotti N, et al. Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO J 2002;21:2332-42.
144. Hall RA, Premont RT, Chow CW, et al. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 1998;392:626-30.
145. Holler C, Freissmuth M, Nanoff C. G proteins as drug targets. Cell Mol Life Sci 1999;55:257-70.
146. Zhong H, Neubig RR. Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 2001;297:837-45.
147. Neubig RR. Regulators of G protein signaling (RGS proteins): novel central nervous system drug targets. J Pept Res 2002;60:312-36.
148. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001;53:1-24.
149. Pierce KL, Lefkowitz RJ. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2001;2:727-33.
150. Paulssen RH, Woodson J, Liu Z, Ross EM. Carboxyl-terminal fragments of phospholipase C-beta1 with intrinsic Gq GTPase-activating protein (GAP) activity. J Biol Chem 1996;271:26622-9.
151. Hurley JH, Anderson DE, Beach B, et al. Structural genomics and signaling domains. Trends Biochem Sci 2002;27:48-53.
152. 13. Science 1998;280:2112-4.
153. de Rooij J, Zwartkruis FJ, Verheijen MH, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396:474-7.
154. Ma YC, Huang JY, All S, et al. Src tyrosine kinase is a novel direct effector of G proteins. Cell 2000;102:635-46.
155. Peterson YK, Bernard ML, Ma H, et al. Stabilization of the GDP-bound conformation of Gialpha by a peptide derived from the G-protein regulatory motif of AGS3. J Biol Chem 2000;275:33193-6.
156. Natochin M, Gasimov KG, Artemyev NO. Inhibition of GDP/GTP exchange on G alpha subunits by proteins containing G-protein regulatory motifs. Biochemistry 2001;40:5322-8.
157. Kimple RJ, Kimple ME, Betts L, et al. Structural determinants for GoLoco-induced inhibition of nucleotide release by Galpha subunits. Nature 2002;416:878-81.
158. Kumaramanickavel G, Maw M, Denton MJ, et al. Missense rhodopsin mutation in a family with recessive RP. Nat Genet 1994;8:10-1.
159. Dryja TP, Finn JT, Peng YW, et al. Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci U S A 1995;92:10177-81.
160. Nathans J, Davenport CM, Maumenee IH, et al. Molecular genetics of human blue cone monochromacy. Science 1989;245:831-88.
161. Nathans J, Maumenee IH, Zrenner E, et al. Genetic heterogeneity among blue-cone monochromats. Am J Hum Genet 1993;53:987-1000.
162. Weitz CJ, Miyake Y, Shinzato K, et al. Human tritanopia associated with two amino acid substitutions in the blue-sensitive opsin. Am J Hum Genet 1992;50:498-507.
163. Kohl S, Baumann B, Rosenberg T, et al. Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet 2002;71:422-45.
164. Kohl S, Marx T, Giddings I, et al. Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel. Nat Genet 1998;19:257-9.
165. Kohl S, Baumann B, Broghammer M, et al. Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet 2000;9:2107-16.
166. Gwinn MR, Sharma A, De Nardin E. Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis. J Periodontol 1999;70:1194-201.
167. Seifert R, Wenzel-Seifert K. Defective Gi protein coupling in two formyl peptide receptor mutants associated with localized juvenile periodontitis. J Biol Chem 2001;276:42043-9.
168. Siffert W, Rosskopf D, Siffert G, et al. Association of a human G-protein b3 subunit variant with hypertension. Nat Genet 1998;18:45-8.
169. Rosskopf D, Manthey I, Habich C, et al. Identification and characterization of Gbeta3s2, a novel splice variant of the G-protein beta3 subunit. Biochem J 2003;371:223-32.
170. Williamson EA, Ince PG, Harrison D, et al. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. Eur J Clin Invest 1995;25:128-31.
171. Riminucci M, Collins MT, Lala R, et al. An R201H activating mutation of the GNAS1 (Gsalpha) gene in a corticotroph pituitary adenoma. Mol Pathol 2002;55:58-60.
172. Tordjman K, Stern N, Ouaknine G, et al. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. J Clin Endocrinol Metab 1993;77:765-79.
173. Williamson EA, Daniels M, Foster S, et al. Gs alpha and Gi2 alpha mutations in clinically non-functioning pituitary tumours. Clin Endocrinol (Oxf) 1994;41:815-20.
174. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.
175. Suarez HG, du Villard JA, Caillou B, et al. gsp mutations in human thyroid tumours. Oncogene 1991;6:677-9.
176. Goretzki PE, Lyons J, Stacy-Phipps S, et al. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992;16:576-81.
177. Shen Y, Mamers P, Jobling T, et al. Absence of the previously reported G protein oncogene (gip2) in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1996;81:4159-61.
178. Ichikawa Y, Yoshida S, Suzuki H, et al. Mutation analysis of gonadotropin receptor and G protein genes in various types of human ovarian tumors. Jpn J Clin Oncol 1996;26:298-302.
179. Gicquel C, Dib A, Bertagna X, et al. Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis. Eur J Endocrinol 1995;133:166-72.
180. Reincke M, Karl M, Travis W, Chrousos GP. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab 1993;77:1419-22.
181. Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 1994;79:890-3.
182. Liu J, Litman D, Rosenberg MJ, et al. A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. J Clin Invest 2000;106:1167-74.
183. Tsigos C, Arai K, Hung W, Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 1993;92:2458-61.
184. Clark AJ, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993;341:461-2.
185. Baumann G, Maheshwari H. The dwarfs of Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Paediatr Suppl 1997;423:33-8.
186. Abramowicz MJ, Duprez L, Parma J, et al. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 1997;99:3018-24.
187. Layman LC, Cohen DP, Jin M, et al. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998;18:14-5.
188. de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997;337:1597-602.
189. Kremer H, Kraaij R, Toledo SP, et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 1995;9:160-4.
190. Gromoll J, Simoni M, Nordhoff V, et al. Functional and clinical consequences of mutations in the FSH receptor. Mol Cell Endocrinol 1996;125:177-82.
191. sa in patients with gain and loss of endocrine function. Nature 1994;371:164-8.
192. Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 1994;8:303-37.
193. Svensson PJ, Von Tell D, Molander ML, et al. A heterozygous frameshift mutation in the endothelin-3 (EDN-3) gene in isolated Hirschsprung's disease. Pediatr Res 1999;45:714-77.
194. Puffenberger EG, Hosoda K, Washington SS, et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 1994;79:1257-66.
195. Attie T, Till M, Pelet A, et al. Mutation of the endothelin-receptor B
196. Abe Y, Sakurai T, Yamada T, et al. Functional analysis of five endothelin-B receptor mutations found in human Hirschsprung disease patients. Biochem Biophys Res Commun 2000;275:524-31.
197. Edery P, Attie T, Amiel J, et al. Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 1996;12:442-4.
198. Hofstra RM, Osinga J, Tan-Sindhunata G, et al. A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat Genet 1996;12:445-7.
199. Ushikubi F, Okuma M, Kanaji K, et al. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 1987;57:158-64.
200. Hirata T, Kakizuka A, Ushikubi F, et al. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994;94:1662-7.
201. van den Ouweland AM, Dreesen JC, Verdijk M, et al. Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus. Nat Genet 1992;2:99-102.
202. Pan Y, Metzenberg A, Das S, et al. Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat Genet 1992;2:103-16.
203. Rosenthal W, Seibold A, Antaramian A, et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 1992;359:233-5.
204. Okamoto S, Hisaoka M, Ushijima M, et al. Activating Gs (alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch 2000;437:133-7.
205. Eddy MC, Jan De Beur SM, Yandow SM, et al. Deficiency of the alpha-subunit of the stimulatory G protein and severe extraskeletal ossification. J Bone Miner Res 2000;15:2074-83.
206. Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002;346:99-106.
207. Ahmed SF, Barr DG, Bonthron DT. GNAS1 mutations and progressive osseous heteroplasia. N Engl J Med 2002;346:1669-71.
208. Karaplis AC, He B, Nguyen MT, et al. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 1998;139:5255-8.
209. Zhang P, Jobert AS, Couvineau A, Silve C. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J Clin Endocrinol Metab 1998;83:3365-8.
210. Schipani E, Kruse K, Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995;268:98-100.
211. Taussig R, Tang WJ, Hepler JR, Gilman AG. Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases. J Biol Chem 1994;269:6093-100.
212. Jordan JD, Carey KD, Stork PJ, Iyengar R. Modulation of rap activity by direct interaction of Galpha(o) with Rap1 GTPase-activating protein. J Biol Chem 1999;274:21507-10.
213. Chen LT Gilman AG, Kozasa T. A candidate target for G protein action in brain. J Biol Chem 1999;274:26931-8.
214. Wilkie TM, Scherle PA, Strathmann MP, et al. Characterization of G-protein alpha subunits in the Gq class: expression in murine tissues and in stromal and hematopoietic cell lines. Proc Natl Acad Sci U S A 1991;88:10049-53.
215. Watson AJ, Aragay AM, Slepak VZ, Simon MI. A novel form of the G protein beta subunit Gbeta5 is specifically expressed in the vertebrate retina. J Biol Chem 1996;271:28154-60.